U.S. markets open in 8 hours 19 minutes

Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
51.20-0.37 (-0.72%)
At close: 04:00PM EDT
51.20 0.00 (0.00%)
After hours: 04:28PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close51.57
Bid0.00 x 800
Ask0.00 x 1000
Day's Range49.74 - 51.70
52 Week Range45.20 - 104.38
Avg. Volume684,906
Market Cap3.586B
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-6.87
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est111.65
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RARE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Ultragenyx Pharmaceutical Inc.
    Daily – Vickers Top Buyers & Sellers for 04/20/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NOVATO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 27,500 shares of common stock of the company and 14,500 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approv

  • Zacks

    Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

    Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

  • Benzinga

    Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance

    Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Q2 sales reached $89.3 million, up from $86.97 million a year ago, beating the consensus of $87.51 million. The company recognized $64.0 million in Crysvita (burosumab) revenue in the Ultragenyx territories, including $51.6 million in collaboration revenue in the North American profit share territory and net product sales in other territories regions of $12.4 million. Yoyalty revenue related to European Crysvita sales was $5.4 million. Dojolvi's (tr